Εκπαιδευτικά προγράμματα
Λίστα αντικειμένων

Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


https://ashpublications.org/blood/article/doi/10.1182/blood.2019003471/430032/Mutational-profile-and-benefit-of-gemtuzumab
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Our clinical practice and SOP for AML elderly just
published.
https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2019003662/429643/Is-There-an-Optimal-Conditioning-for-Older?redirectedFrom=fulltext
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


https://ashpublications.org/blood/article/doi/10.1182/blood.2019002959/430249/Molecular-MRD-status-and-outcome-after
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Λοιμώξεις από JCV και BKV σε
ανοσοκατεσταλμένους ασθενείς.
Presenter: Dr Liga
Participants: Prof.Spyridonidis, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Discrepancies between premortem clinical diagnoses and
postmortem
autopsy diagnoses were evaluated. Of 185 patients who
underwent autopsy, 35 patients (18.8%) had
a total of 41 missed infections. Five
patients (2.7%) had >1 missed infection. Of
the 41 missed infections, 18 (43.9%) were viral,
16 (39.0%) were fungal, 5 (12.2%) were...


We decided a policy change and accorrdigly we write the
new SOP. MM
patients will receive non cryopreserved stem cell
grafts.
Presenter: Prof. Spyridondiis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Verigou


A phase II study if vedo in GvHD prevention was presented.
This is of
major importance since we run the phase III vedo
study.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Verigou


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Verigou


Results of the Prospective Randomized HOVON-96 Trial in
Recipients of
Matched Related and Unrelated Donors were presented in ASH
2019, plenary
session
PTCY is better than CSI standrd treatment
https://ashpublications.org/blood/article-abstract/134/Supplement_1/1/427807/Post-Transplantation-Cyclophosphamide-after?redirectedFrom=fulltext
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Verigou


General principles
- We use the lowest effective dose of prednisone or
methylprednisolone.
- We use topical therapy to supplement systemic treatment. (eg
oral budesonide together with beclomethasone)
-We use follow-up endoscopy to evaluate the response to
treatment in patients with persistent
diarrhea. Absence of clinical or...


NPM1_Spyridonidis_EAE_2019
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Verigou


A paper illustrating the hardle in making decisions in
BMT.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Verigou


Presenter: Dr Liga
Participants: Prof.Spyridonidis, Dr Spyridis, Dr Verigou


A retrospective matched paired analysis of EBMT
shows the superiority in
regards to GFRS of PTCY vs ATG in MMUD transplantation.
Prospective
randomized should confirm these reults.
Presenter: Prof.A Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Verigou


In cases of relapse after allo-HCT, up to 50% of patients
have
cytogenetic or molecular evolution of their disease
[15].A
recent analysis in patients with MDS suggested that
relapse
after allo-HCT is driven by subclones evolving from
founding
clones existing before allo-HCT but harboring new
aberrations
[11], arguing for clonal...


Νεότερα δεδομένα στη θεραπευτική αντιμετώπιση της
Οξείας Λεμφοβλαστικής Λευχαιμίας με τη σύγχρονη ανοσοθεραπεία.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Verigou


Long term results of the phase III study were published.
They confirm
our practice in our Tx center
Presenter: Prof. Spyridondis
Particpants: Dr Liga, Dr Spyridis, Dr Verigou
Acute GVHD prophylaxis plus ATLG after myeloablative
allogeneic
haemopoietic peripheral blood stem-cell transplantation
from
HLA-identical siblings in patients with acute myeloid
leukaemia...


Optimal conditioning for ALL. Does it
exist?
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Verigou


